Insulin-producing Cells from Adult Human Bone Marrow Mesenchymal Stromal Cells Could Control Chemically Induced Diabetes in Dogs

• Published in: Cell transplantation Vol. 27; no. 6; pp. 937 - 947
• Main Authors: Gabr, Mahmoud M, Zakaria, Mahmoud M, Refaie, Ayman F, Ismail, Amani M, Khater, Sherry M, Ashamallah, Sylvia A, Azzam, Maha M, Ghoneim, Mohamed A
• Format: Journal Article
• Language: English
• Published: Thousand Oaks Sage Publications Ltd 01.06.2018; SAGE Publishing
• Subjects: Bone marrow; Cell differentiation; Diabetes; Diabetes mellitus (insulin dependent); Dogs; Glucose; Glucose tolerance; Immunofluorescence; Immunological tolerance; Insulin; Mesenchymal stem cells; Mesenchyme; Pancreas; Stem cells; Stromal cells
• ISSN: 0963-6897; 1555-3892
• DOI: 10.1177/0963689718759913

Ten mongrel dogs were used in this study. Diabetes was chemically induced in 7 dogs, and 3 dogs served as normal controls. For each diabetic dog, 5 million human bone marrow–derived mesenchymal stem cells/kg were differentiated to form insulin-producing cells using a trichostatin-based protocol. Cells were then loaded in 2 TheraCyte capsules which were transplanted under the rectus sheath. One dog died 4 d postoperatively from pneumonia. Six dogs were followed up with for 6 to 18 mo. Euglycemia was achieved in 4 dogs. Their glucose tolerance curves exhibited a normal pattern demonstrating that the encapsulated cells were glucose sensitive and insulin responsive. In the remaining 2 dogs, the fasting blood sugar levels were reduced but did not reach normal values. The sera of all transplanted dogs contained human insulin and C-peptide with a negligible amount of canine insulin. Removal of the transplanted capsules was followed by prompt return of diabetes. Intracytoplasmic insulin granules were seen by immunofluorescence in cells from the harvested capsules. Furthermore, all pancreatic endocrine genes were expressed. This study demonstrated that the TheraCyte capsule or a similar device can provide adequate immunoisolation, an important issue when stem cells are considered for the treatment of type 1 diabetes mellitus.